ALGS (Aligos Therapeutics, Inc.) Wutah bathi EPS kuartalan

Aligos Therapeutics (ALGS) - logo korporat

Aligos Therapeutics (ALGS) develops advanced methods for combating chronic viral liver diseases. Quarterly earnings per share (EPS) growth clearly demonstrates the dynamics of this process, with the indicator standing at 31.50. High R&D expenditures and FDA certification create significant barriers to entry. Simultaneously, the company is implementing ESG standards to ensure ethical research and environmentally sustainable laboratories.

Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan aligos.com (ALGS): kanggo periode 04.07.2022 - 14.11.2026

Rincian metrik keuangan lan pasar Aligos Therapeutics (ALGS)

- rega saham lan konsensus proyeksi valuasi:
Kutipan saham aligos.com|ALGS - Bagan rega target
- indikator valuasi pasar bisnis:
Kapitalisasi pasar Aligos|ALGS - Total Nilai Perusahaan
- indikator nilai aset resik miturut neraca:
Aset Bersih saben Siji Saham Aligos Therapeutics|ALGS - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku aligos.com|ALGS - Total Aset Perusahaan
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas Aligos Therapeutics|ALGS - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal aligos.com|ALGS - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku Aligos|ALGS - Tanggungan jangka dawa|Utang jangka cendhak perusahaan Aligos Therapeutics|Likuiditas cepet aligos.com
- rincian bathi lan kelipatan pasar:
ALGS - Asil keuangan resik|Bathi mangsa ngarep Aligos Therapeutics|ALGS - Nilai perusahaan marang bathi resik|Prakiraan rega marang bathi aligos.com|ALGS - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Aligos|ALGS - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Aligos Therapeutics|ALGS - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan aligos.com|ALGS - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Aligos Therapeutics
- indikator pendapatan dodolan lan penghasilan bisnis:
ALGS - Pendapatan lan volume dodolan|Prakiraan pendapatan perusahaan aligos.com|ALGS - Rasio rega marang dodolan|Multiplikator Forward P/S Aligos
Analisis kabeh metrik perusahaan:Aligos Therapeutics Inc. - ALGS
Produk asil prodhuksi Aligos Therapeutics

Investors are verifying the issuer's resilience through earnings per share dynamics, assessing the business's ability to generate cash flow. The current value of 31.50 regarding the quarterly EPS growth trend reflects the rate of change in net income, which for the biopharmaceutical sector of Aligos Therapeutics (ALGS) is more critical than macro cycles, as it correlates directly with the success of clinical trials and R&D cost efficiency.

Pesaing Aligos Therapeutics

ARWR (Arrowhead Pharmaceuticals, Inc.) - Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan|MIRM (Mirum Pharmaceuticals, Inc.) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|DVAX (Dynavax Technologies) - Wutah bathi EPS kuartalan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan Tekmira Pharmaceuticals ABUS|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan Inventiva S.A. (IVA)|GYRE (gyretx.com) - Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan ASMB (Assembly Biosciences, Inc.)|Wutah bathi EPS kuartalan Galectin Therapeutics, Inc. GALT|GNFT - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|DRRX: Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|BIVI: Wutah bathi EPS kuartalan|GLMD - Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan|NDRA (ENDRA Life Sciences Inc.) - Wutah bathi EPS kuartalan|HEPA - Wutah bathi resik saben saham sajroning taun lumaku